Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solidtumors (FORAGER-1): Dose optimization
  • Drakaki, A.
  • Park, S. H.
  • Gauna, D. E. Castellano
  • Siefker-Radtke, A. O.
  • Reimers, M. A.
  • 외 15명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solidtumors (FORAGER-1): Dose optimization
저자
Drakaki, A.Park, S. H.Gauna, D. E. CastellanoSiefker-Radtke, A. O.Reimers, M. A.Gao, X.Rha, S. Y.Galsky, M. D.Tripathi, A.Sarfaty, M.Mamtani, R.Zhang, T.Sonpavde, G. P.Vinceneux, A.Loriot, Y.Garmezy, B.Szymczak, S.Zhang, Z.Widau, R.Iyer, G.
DOI
10.1016/j.annonc.2025.08.3684
발행일
2025-09
유형
Meeting Abstract
저널명
Annals of Oncology
36